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Breast cancer, along with most cancers, is preceded by a precancerous state. 
The majority of cancer research is focused on understanding and targeting cells 
once they have reached the neoplastic stage. Advancements in early detection 
have identified the presence of preneoplastic lesions in the breast reporting that 
cells in these lesions remain phenotypically normal but have pro-growth genetic 
alterations. These emerging preneoplastic cells carry oncogenic drivers are 
significantly predisposed to developing tumors, but can stay in a latent state 
resembling normal quiescent cells in premalignant tissues. Expansion of such 
preneoplastic populations underlies a key cellular process driving premalignant 
development and is a hallmark in precancerous lesions and premalignant tissue 
fields surrounding tumors of epithelial origins such as the breast. Despite the 
indolent nature, preneoplastic clonal expansion is crucial to propagating and 
facilitating the accumulation of oncogenic alterations that drive clonal evolution of 
tumorigenesis and ultimately leads to neoplastic progression. The cellular 
controls of preneoplastic clonal expansion during premalignant development 
remain largely unknown. A major barrier to investigating preneoplastic clonal 
expansion is the lack of experimental models to recapitulate quiescent 
preneoplastic cells in premalignant tissues. Throughout my PhD research, I have 
devised a three-dimensional organoid model of quiescent preneoplastic breast 
cells. Using this model system, I have found that breast cells with aberrant AKT 
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activation have distinct molecular controls that contribute to an altered 
homeostatic state of quiescence. This altered state underlies the maintenance of 
growth-arrest under normal conditions and the proliferative advantage in 
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Chapter 1: Introduction 
1.1 Breast Cancer Prevalence  
About 1 in 8 women in the United States will develop invasive breast cancer over 
the course of her lifetime. It is the most commonly diagnosed cancer among 
women and accounts for approximated 26% of all incident cancers among 
women49,52. Each year 400,000 women die of breast cancer, making it the 
second-leading cause of cancer deaths among American women after lung 
cancer. The lifetime risk of dying of breast cancer is approximately 3.4%52. The 
international incidence of breast cancer in women varies drastically. While the 
highest incidence occurs in the United States and Northern Europe, the lowest 
incidence occurs in Asia52. Unfortunately, incidence rates have been rising in 
Asian countries in recent years as these regions make the transition towards a 
Western-style economy and pattern of reproductive behavior. Age and family 
history can affect the risk of breast cancer development52,56. Age sharply 
increases breast cancer incidence rates becoming substantial before 50 years of 
age52. Although breast cancer cannot be prevented currently, early detection can 
increase treatment options and chances of survival. The size and spread of 
breast tumors are two of the most important factors in predicting the prognosis or 
outlook of a women with the disease. Women whose breast cancer is detected at 
an early stage have a 93%+ survival rate in the first five years52. 
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Cancer prevention would have a profound impact on cancer-associated 
mortality and morbidity but it requires in-depth knowledge of physiological 
processes underlying tumor initiation57. Tumorigenesis of breast cancer, and 
many other cancers, is considered a multi-step and linear progression through 
sequential stages of preneoplastic lesions, neoplastic lesions, and ultimately 
invasive cancer56,57. A number of changes occur in cells as they progress 
towards a greater degree of malignancy. During this process, genomic instability 
occurs, followed by alterations in oncogenes, onco-suppressor genes, and DNA 
repair genes, along with surface alterations and alterations in intercellular 
interactions which leads to the consequent changes in the signal transduction 
network49,63. The progressive accumulation of genetic changes generates 
autonomously growing neoplastic lesions49. Cells in these lesions are both 
genetically and phenotypically altered49,56. The relationship between these 
changes and the progression towards neoplasia is not understood. 
One of the major challenges of cancer research has been the discovery of 
tools for efficient prevention of malignancy49,56. The identification of very early 
biochemical, molecular, and morphologic changes that predisposes normal cells 
to malignant transformation plays a pivotal role. In principle, tumor prevention 
would imply the protection against tumor initiation or an efficacious preventative 
strategy to block the evolution of initiated cells to malignancy. Early identification 
of pre-neoplastic lesions is a prerequisite for efficacious prevention.  
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1.2 Preneoplastic Lesions 
Pre-neoplastic breast lesions represent a broad spectrum of lesions with a 
variable risk of progression to carcinoma59,63. Various types of preneoplastic 
lesions have been identified in breast tissue. Common pre-neoplastic breast 
lesions seen in benign breast lesions are lobular neoplasia in situ (LIN), 
papilloma, atypical hyperplasia (AH), and flat epithelial atypia (FEA)59. In benign 
breast lesions which show associated findings of preneoplastic lesions, genetic 
alterations begin to occur quite quickly leading to unbalanced proliferative and 
apoptotic signals that may initiative neoplastic proliferation59. Regulation of cell 
proliferation is a vital physiologic phenomenon that helps to prevent malignant 
transformation within a cell population56,59. The evolution of clonal expansion of 
preneoplastic cells in preneoplastic lesions pushes these lesions to progress into 
more cancerous lesions1. Although the level of proliferation seen in more 
progressed lesions is very high and disorganized, proliferative levels in 
preneoplastic cells remain fairly low. For example, previous studies looked at the 
proliferation rates of preneoplastic atypical hyperplasia lesions in the breast, the 
median value for percent positive cells for Ki67 was 1.0% with the 75th percentile 
being 2.3%59. This highlights that preneoplastic lesions contain preneoplastic 
quiescent cells that have an advantage to clonally expand but are phenotypically 
different than neoplastic cells.  
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There is no way to determine the presence of a preneoplastic lesion by 
reviewing a mammogram or other breast imaging study59,64. Improvements in 
clinical radiology and the routine ruse of large core needle biopsies have led to 
an increased detection rate of early precursor lesions in the breast64. This has 
provoked questions regarding the role of these lesions in the evolution of breast 
cancer, specifically whether the presence of preneoplastic lesions increases the 
risk of breast cancer development in the future. Results exploring this risk 
concluded that the presence of a preneoplastic lesion in the breast like AH 
increases the likelihood that breast cancer will develop49,56. Specifically, data has 
shown that 25 years after an AH biopsy, breast cancer (either in situ or invasive) 
developed in 30% of the women71,72. This risk is also increased more if the 
women have a family history of breast cancer72.  
These advancements of early detection have sparked wanting to know 
more about premalignant stages. Many studies over the past decades have 
focused on delineating the genome of preneoplastic lesions. These 
comprehensive gene-expression studies in breast-cancer progression have 
shown that similar and progressive transcriptional and epigenetic alterations 
found in preneoplastic lesions of the breast, are also found in carcinoma in situ 
and invasive carcinoma of the breast, which provides additional evidence for the 
precursor role of preneoplastic lesions49.  
Unfortunately, delineating the genome is not sufficient. For example, 
preneoplastic breast lesions have been reported to exhibit decreased p2774 
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levels and PIK3CA mutations73. In addition, it is established that the 
microenvironment and stroma induce cells to progress to malignancy. The 
regulation of proliferation versus quiescence is a key determinant of the fate of 
tumor growth. This critical decision is tightly coupled with interactions between 
preneoplastic cells, host cells, and immune mechanisms. Specific immune 
effectors and secreted factors (including cytokines and chemokines) have been 
implicated in the initiation of tumorigenesis and tumor growth. Similarly, 
inflammation can be associated with increased tumorigenesis; chronic 
inflammation has been associated with a poorer breast cancer prognosis56,71. 
Consequently, the presence or absence of immune effectors is associated with a 
favorable or non-favorable prognosis depending on tissue type, thereby 
indicating the complexity of the interaction between the host immune system and 
the evolving tumor56,71,72. Additionally, fibroblasts, a major cell type of the 
microenvironment, have thought to favor tumor progression via secreted 
factors75. Despite the understanding of characteristics associated with breast 
fibroblasts, further investigation into their role and involvement of the breast 
cancer microenvironment will yield important and needed insights to the 
convoluted connections between cancer cells and the stroma. Therefore, 
understanding how this genome manifests on a cellular and molecular level is 
needed to gain a better in-depth understanding of preneoplastic cells and 
lesions. Identifying the underlying mechanisms of how preneoplastic cells exploit 
the stroma and take advantage of the microenvironment in order to expand will 
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deepen the understanding of early stages of breast cancer initiation allowing for 
eventual intervention and prevention.  
 
1.3 Thesis Aims 
During my Ph.D. tenure, I have furthered our understanding of the 
mechanistic insights of the clonal expansion advantage that quiescent, 
preneoplastic cells have. In Chapter 3, I introduce a model system that is able to 
recapitulate the genetic and proliferative features of quiescent breast 
preneoplastic cells and, importantly, provide a platform to interrogate the cellular 
control of quiescent preneopalstic cells at the mechanistic level. In Chapter 4, I 
show how regardless of having an oncogenic, pro-growth alteration, 
preneoplastic cells are able to maintain quiescence is normal conditions through 
cell-intrinsic feedback signaling mechanisms through altered genetic expression 
and modulating the microenvironment. In Chapter 5, I show that although the 
oncogenic alterations do not directly promote proliferation, cells are sensitive to 
non-native growth factors priming the cells to proliferate under specific 
environments that involve genetic and microenvironment interactions. Finally, in 
Chapter 6 I discuss that my research suggests that altered homeostatic controls 
of quiescence may also underlie the maintenance and selective clonal expansion 
of indolent preneoplastic cells during premalignant development and what the 
overall impact and implications of these findings represent.  
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Chapter 2: Materials and Methods 
2.1 Buffers and Solutions 
2.1.1 Protein Lysis Buffer 
RIPA Buffer (ThermoFisher Scientific) 
PBS (ThermoFisher Scientific) 
Halt Protease and phosphatase inhibitor (ThermoFisher Scientific) 
2.1.2 Western Blot Buffers 
Western Blot 4X Reducing Sample Buffer 
Laemmli’s SDS-Sample Buffer (4X, Reducing) (Boston BioProducts) 
Western Blot Running Buffer 
Tris-Glycine-SDS Running Buffer (10X) (Boston BioProducts) 
Western Blot Transfer Buffer 
Transfer Buffer (10X) (Boston BioProducts) 
10% Methanol (ThermoFisher Scientific) 
Western Blot Wash Buffer 
Tris-Buffered Saline (20X) (Boston BioProducts) 




Western Blot Stripping Buffer 
Membrane Stripping Buffer (4X) (Boston BioProducts) 
2.1.3 RNA Isolation Buffers 
RNeasy Mini Kit (Qiagen) 
TRIzol Reagent (Ambion Life Technologies) 
2.1.4 Organoid Immunofluorescent Reagents 
Fixation Buffer: 4% PFA 
Paraformaldehyde, 16% (Ted Pella, Inc.) 
PBS  
1X PBS/Glycine Buffer 
3.75 g Glycine  
500 mL PBS 
10X IF Wash Buffer 
2.5 g NaN3 
5 g BSA 
10 mL TritonX-100 (ThermoFisher Scientific) 
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2.5 mL Tween-20 (ThermoFisher Scientific) 
500 mL 10X PBS 
1X PBS/0.5% Triton-X Buffer 
2.5 mL Triton X-100 (ThermoFisher Scientific) 
500 mL 1X PBS 
2.2 Cell Culture 
2.2.2 MCF10A/MCF12A Growth Media 
500 mL DMEM/F12 Medium (ThermoFisher Scientific) 
25 mL Horse Serum (ThermoFisher Scientific) 
100 μL EGF (100 μg/ml) (Peprotech) 
250 μL Hydrocortisone (1 mg/mL) (Sigma-Aldrich) 
50 μL Cholera Toxin (1 mg/mL) (Sigma-Aldrich) 
500 μL Insulin (10 mg/mL) (Sigma-Aldrich) 
2.5 mL Penicillin/Streptomycin (200X) (ThermoFisher Scientific) 
2.2.3 MCF10A Resuspension Media 
400 mL DMEM/F12 Medium (ThermoFisher Scientific) 
100 mL Horse Serum (ThermoFisher Scientific) 
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2.5 mL Penicillin/Streptomycin (200X) (ThermoFisher Scientific) 
2.2.4 3D Cell Culture Media Base 
500 mL DMEM/F12 Medium (ThermoFisher Scientific) 
10 mL Horse Serum (ThermoFisher Scientific) 
250 μL Hydrocortisone (1 mg/mL) (Sigma-Aldrich) 
50 μL Cholera Toxin (1 mg/mL) (Sigma-Aldrich) 
500 μL Insulin (10 mg/mL) (Sigma-Aldrich) 
2.5 mL Penicillin/Streptomycin (200X) (ThermoFisher Scientific) 
2.2.5 3D Cell Culture Media + EGF 
50 mL 3D Cell Culture Media Base 
2.5 μL EGF (100 μg/ml) (Peprotech) 
2.2.6 NIH-3T3 Growth Media 
500 mL Dulbecco’s Modified Eagle’s Media (DMEM) (ThermoFisher Scientific) 
2.2.7 T47D Growth Media  
400 mL RPMI (ThermoFisher Scientific) 
10% FBS (ThermoFisher Scientific) 
0.01mg/ml Insulin (Sigma-Aldrich) 
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2.3 3D Cell Culture Studies 
Three-dimensional cultures of MCF-10A and MCF12-A cells were set up 
in 8-well chamber slides (BD Biosciences), or coverglass bottom 8-chamber 
slides (MatTekII) as previously described with 4500-5000 cells in Assay Media + 
2% MatrigelTM. Media was replaced every 4 days. To induce oncogene and 
reporter expression in growth-arrested acini, cultures were treated on Day 16 
with fresh media containing 1 ug/mL doxycycline. Inhibitor and chemokine 
treatments were performed on Day 18 by replacing with fresh media containing 1 
ug/mL doxycycline, and the corresponding concentration for inhibitors, 
chemokines, or vehicle controls. The cultures were analyzed on Day 20. 
Single-cell transduction in growth-arrested mammary organoids were 
conducted as described. On Day 16, 3D cultures were infected with 
corresponding lentiviruses diluted in Assay Media without EGF for 6-8 hours at 
37oC. Virus dosages were adjusted to infect less than 1 cell per 10 acini to 
achieve sporadic single-cell infection. The viruses were removed, and the 
chamber wells were rinsed with 500μl PBS and replaced with normal 3D Assay 
Media without Matrigel. Doxycycline was added at 1g/mL on the following day 
along with drug treatment or vehicle control as indicated. Complete media was 
changed every 4 days. Acinar structures were analyzed eight days after 




2.4.1 Cell Lines 
MCF10 cells were a kind gift from Joan Brugge (Harvard Medical School). 
MCF12A cells were purchased from ATCC. NIH-3T3 and NIH-3T3 CAV-KO cells 
were obtained from Dr. Zachary Schafer (University of Notre Dame). 
2.4.2 Viral Vectors 
The lentivector pLT-IGSP (IRES-GFP-sv40-puro) was generated by subcloning a 
SV40-puro cassette from the pBABE-puro plasmid (Addgene Plasmid #1764) 
and inserted downstream of IRES-GFP in the pLT-iG lentivector. pLT-iG 
lentivector containing the tetracycline response element (TRE) from pTre-Tight 
(Clontech), multiple cloning sites, and a downstream IRES-GFP cassette from 
pIRES2-GFP (Clontech) were described previously 1. pLT-AKT-E17K-iGSP was 
generated by PCR using the hAKT1 coding sequence as template and primers 




subcloning into the pLT-iGSP vector. Products are confirmed by sequencing. 
pLT-myrAKT1-iGSP was generated by subcloning the myrAKT1 fragment from 
pLNCX myrAKT1 (Addgene Plasmid #17245) in the pLT-iGSP vector. pLKO 
shRNA knockdown constructs were obtained from GE Dharmacon. p57 
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knockdown clone #39678 (Clone#1) and #10486 (Clone#2) were used. pLT-
CXCR4-iGSP is generated by subcloning from pcDNA3.1-DYK-CXCR4 
purchased from GenScript. All coding sequences were validated by sequencing.  
2.5 Western Blot 
2.5.1 Protein lysis, quantification, and sample preparation 
Plates for protein harvest were put on ice, washed twice with cold 1xPBS and 
PBS was removed. Cells were lysed on ice with cold RIPA/Halt and incubated for 
15 minutes. Plates were then scraped and lysate was collected into 
microcentrifuge tube and pulled through a 27-gauge needle 3-5 times. Lysate 
was incubated on ice for 15 minutes and then spun at maximum speed 
(>14,000xg) for 10 minutes at 4oC. Supernatant was collected and snap frozen in 
liquid N2. Samples were stored at –80oC. 
Protein samples were quantified using the PierceTM BCA Protein Assay Kit 
(#23227) 
Samples were thawed on ice and 15ug of protein, water, and 4x SDS gel loading 
buffer with DTT (2ME) were combined to total 20ul. Samples were then heated 
for 5-10 minutes at 95 oC and set on ice before loaded into the gel.  
2.5.2 Running, transfer, detection 
Gels were run for 30 minutes at 230V and then immediately proceeded to 
transfer for 90 minutes at 100mA. Blots were then blocked overnight with 
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Blocking Buffer. The blot was then incubated with 1:100 dilution of primary 
antibody for 1 hour, washed, and incubated with 1:5000 HRP-conjugated 
secondary antibody for 1 hour.  
ECL reagent (Luminata Crescendo) was added to membrane for detection. 
 
2.6 Immunohistochemistry staining 
Immunofluorescent analyses were performed as previously described. Briefly, 
cells were fixed at room temperature for 30 minutes with 4% paraformaldehyde. 
Primary antibodies were used at 1:100-1:200 and incubated overnight in the dark 
at room temperature. Alexa secondary antibodies (ThermoFisher Scientific) were 
used at 1:200 and incubated for one hour at room temperature. Nuclei were 
counterstained with DAPI. Images were acquired using a Nikon A1RMP confocal 
microscope in the University Imagine Center at the University of Minnesota.  
 
2.7 Molecular Biology Techniques 
2.7.1 Virus production 
Retroviruses and lentiviruses were produced by co-transfecting the 
corresponding viral vectors with packaging vectors pCL-Ampho (retroviruses, 
Imgenex) or psPAX2 and pMD2.G (lentiviruses, Addgene #12260 and #12259) 
into 293T cells with TurboFECT (ThermoFisher Scientific). Virus-containing 
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supernatants were collected on day 2 and 3 following transfection and were 
stored at −80°C. 
 
2.7.2 Isolation and Quantification of RNA 
RNA was collected with TRizol and Chloroform and spun at 10,000xg for 18 
minutes at 4°C. The aqueous phase was removed and combined with 100% 
RNA-free Ethanol. The protocol provided with the RNAeasy Kit was then 
followed.  
 
2.7.3 Generation of cDNA and Gene Detection by quantitative PCR 
3D cells were incubated on ice in Cell Recovery Solution (Corning) for 30 
minutes and washed. RNA was extracted by TRIzol RNA Isolation Reagents 
(ThermoFisher Scientific), and purified using RNeasy (Qiagen). First strand 
cDNA was synthesized using the SuperScript III First-Strand Synthesis System 
according to the vendor protocol. qPCR was perfomed using SYBR Select 
Master Mix and StepOnePlus Real Time PCR System (ThermoFisher Scientific). 
0.2uM primer concentration was used. The following primer sequences were 
used: 
Transcripts were considered to be undetectable when the Ct value was above 
32. qPCR was performed using three individual biological samples in duplicate. 
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ΔΔCt was calculated by normalizing to RPLR0 and average and standard 
deviation were determined. Statistically significant differences were determined 
by Student’s t-test. 
 
2.7.5 Soft Agar Assay 
10,000 cells in 1.5 mL 0.4% Sea Plaque low melt agarose was layered on top of 
a 2 mL 0.5% agarose base layer per well of a 6-well plate. Triplicate samples 
were used. 1 mL of growth media with 1 ug/mL doxycycline and CXCL12 or PBS 
was overlaid on the solidified cells/agarose mix. Media was changed every 3 
days for 30 days.  
 
2.9 Antibodies 
Antibody Company Catalog Number Species 
p57 Santa Cruz 
Biotechnology 
SC-1040 Rabbit 
Ki67 ThermoFisher Scientific 180191Z Rabbit 
CXCR4 R&D Systems/ Bio-
Techne 
MAB 172-100 Mouse 
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Beta Actin Sigma Aldrich A1978 Mouse 











2.10 Statistical Analysis 
All cell counting experiments were collected from 3 individual experiments 
with 100 total number of isolated GFP+ organoid structures. Percent of total 
number of Ki67+ cells per nuclei in each organoid were recorded under a Leica 
DMI 3000 fluorescent microscope. Average and SEM (Standard Error Means) of 
the percent of Ki67+ cells were calculated. Statistically significant differences 
were determined by two-tail Student’s t-test and were used for pairwise 
comparison.  
For clonal expansion experiments, acini were fixed in 4% PFA for 20 
minutes at room temperature and counterstained for nuclei with DAPI. Isolated, 
infected acinar structures were scored for expansion and for spatial location of 
18 
 
the infected cells/clones with respect to the structures. GFP-labeled cell clusters 
containing more than one nucleus based on DAPI counterstain were scored as 
expanded clones. Three individual experiments with 80-120 acini counted each 
were analyzed per assay. Means and standard deviations were calculated. 













Chapter 3: Preneoplastic Quiescent Model System 
3.1 Introduction 
Cancer models are the primary tool used by cancer researchers in order 
to test specific hypothesis related to cancer as they allow systemic manipulation 
of known parameters. Ideal models recapitulate both the cellular and molecular 
mechanisms driving cancer progression, can be manipulated to precisely answer 
questions about these mechanisms, and provide reproducible results over a 
period of time.  
With one in eight American women at risk of developing breast cancer 
within her lifetime, understanding the underlying mechanisms that drive breast 
cancer progression is crucial. Neoplastic transformed cells exhibit some of the 
features involved in multi-step carcinogenesis such as morphological changes, 
lack of contact inhibition, independence of their growth from specific growth 
factors, oncogene activation, and tumor suppressor gene inactivation. The 
earliest lesions and genetic transitions usually occur years before a tumor is 
detected. While early stage ductal carcinoma in situ (DCIS) is not considered life 
threatening with a 10-year survival rate of about 90%, this drops dramatically to 
under 10% when the cancer is detected at later stages. Based on previous 
studies over the past decades, early detection of breast cancer might provide the 
greatest opportunity for a cure. Unfortunately, little is known about the underlying 
genetic events that trigger the progression of a normal cell into a cancerous one. 
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Therefore, it is imperative to understand the earliest events that trigger this 
progression. The identification of biomarkers and development of selective 
therapeutics targeting key pathways in preneoplastic cells will represent a “holy 
grail” in breast cancer treatment and prevention.  
The mammary gland is composed of an organized ductal network. 
Embedded within the stroma, the branching duct system leads from the collecting 
ducts via the segmental and subsegmental ducts to the terminal duct lobular 
units (TDLUs). Two cell types compose the epithelium of the duct and lobule 
system, namely luminal (secretory) cells and myoepithelial cells. Almost all 
mammary carcinomas develop within the TDLU or the terminal ducts that enter 
the lobular units.  
The regulation of proliferation versus quiescence is a key determinant of 
the fate of tumor growth. While premalignant and pre-invasive breast lesions are 
relatively common, only a small percentage progress to high grade invasive 
breast cancer. Therefore, important biological differences must exist between 
those that remain stable and those that progress into cancer. Emerging 
preneoplastic cells that carry oncogenic drivers are significantly predisposed to 
developing tumors, but can stay in a latent state resembling normal quiescent 
cells in premalignant tissues.  
Currently, little is known about the biology of quiescence and a number of 
obstacles have hindered the study of early tumor progression. This reflects the 
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difficulties in identifying and isolating preneoplastic, quiescent cells in humans, as 
well as the general lack of in vitro experimental systems and scarcity of in vivo 
models. In the past, the lack of experimental systems has greatly hampered the 
mechanistic study of preneoplastic quiescent cells. A major barrier to 
investigating preneoplastic clonal expansion is the lack of experimental models to 
recapitulate quiescent preneoplastic cells in pre-malignant tissues. Non-
transformed cell lines are amenable to genetic manipulation to mimic the 
molecular context of preneoplastic cells, but engineered cells with oncogenic 
alterations tend to proliferate under traditional culture conditions. Tissue 
environment also plays crucial roles in suppressing preneoplastic cells in native 
tissues of animal models2-4, and therefore significantly impedes mechanistic 
study. Modeling pre-malignancy in vitro is complex and has only been made 
possible in the last decade through the advent of three-dimensional acini 
cultures. This model provides a context in which it is feasible to identify genes 
and dissect mechanisms necessary to produce phenotypic alterations similar to 
those observed during malignant progression. These can include luminal filling, 
loss of polarization, and invasive behavior. Although this progress has been 
made, work is still needed to accurately model pre-malignancy in order to 
understand the vents that drive a cell towards a cancer fate. Moving forward 
these models can be used to understand the role of oncogenes that are more 
common to breast cancer.  
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Establishing new models to study preneoplastic quiescent cells in a more 
physiologically relevant environment will lead to a more comprehensive 
understanding of the underlying mechanism of quiescence. A better 
understanding of the regulatory mechanisms and conditions that govern the state 
of preneoplastic quiescence could eventually help identify potential useful 
markers of these cells and health conditions that could be used to evaluate 
patients’ cancer risks potentially leading to a reduction in cancer mortality. 
 
3.2 Model System 
To overcome the limiting hurdles needed to study quiescent preneoplastic 
cells, I recapitulated the molecular and cellular context of premalignant tissues by 
combining genetic tools for inducible oncogenic alterations and three-
dimensional culture of growth-arrested mammary organoids.  
 
3.2.1 Cell Lines 
Since tumor cell lines continue to proliferate under traditional monolayer 
tissue culture conditions on rigid plastic, I used non-transformed, human 
mammary epithelial cells (MCF10A and MCF12A) derived from independent 
individuals5,6. These cells carry features particularly suitable for modeling 
preneoplastic cells. They harbor homozygous deletion at the INK4A/ARF locus7, 
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resulting in p16-loss, a common alteration in preneoplastic mammary cells that 
have bypassed replicative senescence8,9. Otherwise, these cells are diploid and 
genetically stable10,11. They have overcome the replication limit, but do not form 
colonies in soft-agar or tumors in mouse xenografts. Importantly, these mammary 
cells remain subjected to proliferative constraint exerted by suppressive epithelial 
environments in organoid cultures12.  
 
3.2.2 Three-Dimensional Cell Culture 
Cells are seeded on Matrigel, reconstituted basement membrane 
materials that resemble the stiffness and components of the extracellular matrix 
(ECM) in tissue. When seeded on Matrigel, individual mammary cells proliferate 
to for spheroids (Day 0-8), undergo luminal clearing (Day 8-12), and develop into 
growth-arrested organoids that resemble the terminal end bud of the mammary 
gland (Day 16 onwards) 12. These orgnaoids remain growth-arrested in complete 
media containing growth factors and serum12, recapitulating homeostatic 
mammary tissues.  
 
3.2.3 Modeling Preneoplastic Cells 
Aberrant AKT activation is a major driver of tumor growth13 that has also 
been implicated in premalignant development in breast14-20 and other epithelial 
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tissues21. AKT signaling mediates many cellular processes including cell survival, 
proliferation, and metabolism; and has important roles in supporting breast tumor 
growth and progression22,23. However, its contribution to premalignant 
development is less clear. Previous transgenic studies have shown that genetic 
aberrations that deregulate the PI3K/AKT signaling pathway increase incidence 
of mammary tumors only after prolonged latency, but significantly promote tumor 
formation in cooperation with other oncogenic alterations22,24,25, supporting a role 
of AKT signaling in premalignant development. Consistent with this notion, 
aberrant activation of AKT signaling is evident in precancerous breast lesions14-
21,26. AKT1 is used to model activation of the signaling pathway because it has 
the broadest specificity for known AKT substrates, is ubiquitously expressed, and 
has predominant roles in breast tumorigenesis. 
 
3.2.4 Entire Model System of Preneoplastic, Quiescent Cells 
To model quiescent, preneoplastic mammary cells with aberrant AKT 
activation in premalignant tissue, we first engineered cell lines to allow for 
temporal induction of hyperactive AKT signaling. Parental non-transformed 
human mammary cells constitutively expressing the reverse tetracycline trans-
activator (rtTA) (MCF10A/rtTA or MCF12A/rtTA) were transduced with lentiviral 
constructs that contain tetracycline (TET)-inducible myrAKT1 (myristolated AKT1, 
a constitutively active AKT1 variant) and bicistronic IRES (Internal Ribosome-
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Entry Site) mediated GFP reporter (pLT-myrAKT1-iGSP), or IRES-GFP control. 
(Figure 1). 
These cells were then cultured on Matrigel in media without doxycycline 
(Dox, a stable tetracycline analogue) for 16 days to form growth-arrested 
organoids that recapitulate suppressive premalignant tissue environments. 
Growth-arrested organoids were then treated with Dox to induce myrAKT1 and 
GFP reporter expression. These cells have no detectable GFP expression in the 
absence of Dox and efficiently induce reporter expression upon Dox treatment 
(Figure 2).  
 
3.2.5 Preneoplastic Cells Remain Quiescent  
First, I examined the effects of inducing aberrant AKT activation on 
growth-arrested organoids. Percent cycling cells per organoid were determined 
by immunostaining with an antibody against Ki67, a widely used marker in 
laboratories and clinics for all active cell-cycle phases (non-G0[quiescent]). I 
found that the preneoplastic cells in the organoids remain quiescent (0.9±0.2%, 
Figure. 4) despite significant AKT activation as indicated by increased levels of 
phosphorylated-AKT on the cell membrane (Figure 3). Maintenance of 
quiescence was also observed in other preneoplastic mammary cell models 
based from MCF12A organoids with inducible myrAKT1 expression (1.2±0.2%, 
Figure 5) and MCF10A organoids with inducible expression of a pathologically 
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relevant AKT1 mutant in breast cancers20,29 (AKT1-E17K, 0.6±0.2%) (Figure 5). 
Moreover, the low proliferation rate is consistent with that reported in normal 
breast tissues and benign breast lesions (~0.5% to ~3.7%)16,30, and contrasts the 
high proliferation rate (37.3±1.8%, Figure 4) of identical cells with AKT signaling 
induced in actively proliferating spheroids under the same media conditions.  
 
3.2.6 Other Models for Preneoplastic Cells 
Interestingly, using similar lentiviral vectors to activate other common 
oncogenic alterations and co-express a GFP marker, such as c-Myc over-
expression or over-expression of CyclinD in single or all cells within the 
organoids, these preneoplastic cells remain quiescent in culture, similar to the 
GFP-only expressing control. In contrast, over-expression of ErbB2, a receptor 
tyrosine kinase that is over-expressed in 25-30% of breast carcinomas, induces 





With breast cancer being one of the most commonly diagnosed cancers 
among women, cancer prevention would have a profound impact on cancer-
associated mortality and morbidity. To potentially achieve this, in-depth 
knowledge of physiological processes underlying the multi-step and linear 
progression of tumor initiation is required. In principle, tumor prevention would 
imply the protection against tumor initiation or an efficacious preventative 
strategy to block the evolution of initiated cells to malignancy. Therefore, 
understanding how preneoplastic quiescent cells in preneoplastic lesions are 
able to maintain quiescence while carrying oncogenic changes and 
understanding what permissive environments allows them to be advantageous in 
clonal expansion is needed.  
This organotypic system provides a model to study the maintenance of 
preneoplastic, quiescent cells that contain defined oncogenic alterations. Using 
cells with aberrant AKT expression as a model for the early genetic changes in 
preneoplastic cells is representative of all preneoplastic lesions with pro-growth, 
oncogenic alterations and it allows for insight into the underlying mechanisms of 
preneoplastic lesions in general. It also permits convenient genetic manipulation 
and application of non-genetic factors to investigate cellular mechanisms that 
govern preneoplastic quiescence. Altogether, these organoid models recapitulate 
the genetic and proliferative features of quiescent breast preneoplastic cells and, 
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importantly, provide a platform to interrogate the cellular control of quiescent 
preneoplastic cells at the mechanistic level.  
This model system overcomes the major barrier that has impeded 
investigation of preneoplastic clonal expansion and understanding the underlying 
mechanisms that regulate and maintain quiescence. Due to its more 
physiologically relevant environment, a more comprehensive understanding of 
the regulatory mechanisms and conditions that govern the state of preneoplastic 
quiescence can be obtained leading to the identification of useful markers of 
these cells and health conditions. Identifying potential markers and developing 
prognostic markers could be used to evaluate patients’ cancer risks potentially 












Figure 1: Schematic of inducible cassettes and time-line of organoid culture 
models. 
TRE, tetracycline response element; IRES, internal ribosome entry site; rtTA, 
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Figure 2: Representative pictures of Day 20 organoid culture. 
Scale bar, 50m. Inlets, individual organoid. Green, GFP reporter. Blue, DAPI 
nuclear counterstain. Scale bar, 20m.  
 
 


















Figure 3: Representative images of activated AKT in organoid. 
Representative images of activated AKT (phosphor-AKT, pAKT) in organoid 
























Figure 4: Organoid proliferation images and quantification of MCF10A myrAKT1 
cells. 
a) Representative images and b) quantification of proliferating (Day 6) and 
growth-arrested (Day 20) organoids 2 days after doxycycline induction. Graphs 
indicate means and SEM of 100 organoids from three individual experiments. 








Figure 5: Organoid proliferation of MCF10A AKT-E17K and MCF12A myrAKT1 
cells. 
a) Representative images and b) quantification of organoids of Day 20, four days 
after doxycycline induction of GFP or AKT activation. Two cell models, MCF10A 
cells with over-expression of the activating AKT1 mutant E17K found in breast 
cancer patients (MCF10A/AKT1-E17K) and MCF12A cells with myrAKT1 
(MCF12A/myrAKT1). Cells remain largely growth arrest after induction of AKT 
signaling in both models. Graphs indicate means and SEM of 100 organoids from 
three individual experiments. Statistical significant differences were determined 
by Student’s t-test. Scale bars, 10m. 
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Chapter 4: Quiescence Maintenance via Cell-Intrinsic 
Feedback Signaling 
4.1 Introduction 
A critical stage in early breast tumorigenesis is the emergence of 
preneoplastic cells that carry key tumor drivers but remain in a latent state similar 
to normal quiescent cells71,74. Such latent preneoplastic cells have been reported 
in precancerous lesions and tissues surrounding tumors, and are implicated as 
precursors for primary tumors71. Some of these preneoplastic breast lesions 
include flat epithelial atypia (FEA), atypical ductal hyperplasia (ADH), and lobular 
neoplasia in situ (LIN)59. Each of these lesions looks phenotypically normal but 
contains cells that are genetically altered and carry oncogenic drivers. Although 
oncogenic drivers are present, these lesions are not considered malignant and 
the proliferation rates of the cells within these lesions are very low (2-7%) 
suggesting that genetically altered cells carrying oncogenic changes are not 
drivers of proliferation as they remain in a quiescent state68,73.  
Evidence has shown that quiescence does not reflect a longer G1 phase 
within the cell-cycle, but rather a distinct state63. A hallmark of dormancy is that it 
has the capacity to reverse growth-arrest and enter back into the cell cycle46. 
Cells enter quiescence in response to an absence of growth factors or situational 
cues. Whether a preneoplastic quiescent cell re-enters the cell cycle and evolves 
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into a proliferating cancer cell depends on environmental cues- this progression 
is not necessarily only intrinsic. Understanding and identifying the distinguishing 
characteristics and signaling mechanisms that underlie the induction and 
maintenance of preneoplastic quiescence from proliferating preneoplastic cells 
will provide insights into therapeutic strategies to delay or intervene with the 
development of tumors30,63. 
Preneoplastic cells can perplexingly stay latent and resemble normal 
quiescent cells, despite carrying oncogenic drivers 46,63. Sustained growth-arrest 
of these preneoplastic cells raises questions of the control that underlies their 
advantage to clonally expand during premalignant development. Taking 
advantage of the previously mentioned model system to gain mechanistic 
insights into how preneoplastic mammary cells that possess growth-promoting 
alterations stay quiescent in a premalignant tissue environment, I investigated 
the quiescent maintenance in preneoplastic breast cells with aberrant AKT 
signaling, a major tumor driver found in early lesions of the breast and many 
other epithelial tissues13,16.  
Quiescent cells and actively proliferating cells express different gene 
expression patterns and have different functional phenotypes47,49. Since these 
genetically altered cells are not proliferating, I hypothesized that the cell-cycle 
machinery may differ between preneoplastic and control quiescent cells. 
Exploring the cell-cycle machinery, results showed a distinctly different cell-cycle 
regulation in neoplastic quiescent cells that implicates an altered homeostatic 
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state of quiescence that may respond differently to growth stimuli.  The up-
regulation of some cell-cycle machinery was altered in cells with aberrant AKT 
activation along with other anti-proliferative proteins. This up-regulation suggests 
that although aberrant AKT activation is known as a driver of proliferation and 
growth, the pro-growth signal also induces cell-intrinsic feedback signaling 
mechanisms as a constraint signal to maintain a quiescent state. 
Looking further into genetic expression differences of preneoplastic 
quiescent cells when compared to control cells, results showed different genetic 
expression profiles between preneoplastic, quiescent cells and control, quiescent 
cells other than cell-cycle machinery. The major up-regulated gene being 
biglycan (BGN) in preneoplastic, quiescent cells compared to the control cells. 
BGN is a small leucine-rich repeat proteoglycan (SLRP) found in a variety of 
extracellular matrix tissues60. BGN is expressed ubiquitously and is synthesized 
as a precursor from which an N-terminal pro-peptide is cleaved off by bone 
morphogeneic protein (BMP1) to yield the mature form60. When BGN is secreted, 
it interacts via its core protein or GAG chains with numerous components of the 
ECM, including Type I, II, III, and IV collagen and elastin, thereby becoming 
sequestered in the ECM of most organs65. This up-regulation of BGN in the 
preneoplastic, quiescent cells suggests that although aberrant AKT activation is 
present, this pro-growth signal also induces a cell-intrinsic feedback mechanism 





4.2.1 Cell-Cycle Machinery Expression Differs from Normal Cells 
Given the predominant roles of AKT signaling in supporting cell 
proliferation and breast cancer development33, I next investigated how quiescent 
preneoplastic cells with aberrant AKT activation maintain growth-arrest. I noticed 
that in two of the three models tested (Figure 5), the AKT-induced, preneoplastic 
cells have a statistically significant lower percent of Ki67+ population (0.9±0.2% 
AKT1 and 0.6±0.2% E17K) compared to the already low percentage in the 
control populations (2.6±0.5%, Figures 4,5). These observations lead me to 
hypothesize that distinct homeostatic control of cell cycle sustains the growth-
arrest of these preneoplastic cells. I focused on the CIP/KIP family of cyclin-
dependent kinase inhibitors because MCF10A and MCF12A cells have a p16 
loss11, a common change in premalignant breast lesions9. A recent study has 
shown that p57Kip2, but not p21Cip1 nor p27Kip1, mediates insulin- and 
PI3K/AKT-mediated proliferation in mammary epithelial cells34 promoting me to 
investigate the regulation of p57Kip2 in these preneoplastic cells. I found that 
both mRNA transcript and protein levels of p57Kip2 are significantly increased in 
the quiescent preneoplastic cells, compared to the controls (Figures 6 and 7). To 
determine the functional role of this p57Kip2 upregulation, we examined the 
effects of attenuating this p57Kip2 upregulation on the growth-arrest state of the 
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quiescent preneoplastic cells. I found that knockdown of p57Kip2 with two 
individual shRNA clones in the quiescent preneoplastic cells is sufficient to drive 
cell cycle re-entry (Figure 8). Together, these data demonstrated a crucial role of 
p57Kip2 in the maintenance of growth-arrest in preneoplastic cells with aberrant 
AKT signaling and highlight the distinct cell cycle regulation in these cells.  
 
4.2.2 Genetic Expression Differs Between Proliferating and Quiescent Cells 
To explore the genetic expression difference between preneoplastic 
quiescent and normal quiescent cells, I used the same three-dimensional model 
with aberrant AKT active cells to represent quiescent, preneoplastic breast cells. 
I grew both the preneoplastic and control cells to Day 20 and collected RNA for a 
microarray, additionally I collected RNA from both the control and preneoplastic 
cells on Day 6 to represent a proliferating state. The microarray was able to 
compare genetic differences between quiescent control cells and quiescent 
preneoplastic cells, while eliminating normal proliferating to quiescent genetic 
changes using RNA from the proliferating state. Only a handful of genes were 
significantly up-regulated or down-regulated in the preneoplastic quiescent cells 
when compared to the control cells. Representing this data in a heatmap (Figure 
9), it is clear that most genetic changes were down-regulations in the quiescent 
preneoplastic cells when compared to control cells, although there were a few 
up-regulation changes in the quiescent preneoplastic cells. The most significant 
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change was an up-regulation in the gene encoded for the biglycan protein (BGN). 
The BGN gene was expressed at significantly higher levels in the quiescent AKT-
activated cells than in the control quiescent cells. Furthermore, AKT quiescent 
cells also expressed this gene at significantly higher levels than in the AKT-
activated proliferating cells. Re-collecting RNA from Day 6 and Day 20 for both 
control and quiescent cells, I performed a qPCR to confirm the microarray results 
which showed the same trend of a higher expression of BGN RNA in quiescent 
preneoplastic cells than proliferating preneoplastic cells or control cells (Figure 
10). 
Many studies have tried to elucidate the biological role of BGN. Recent 
studies have shown evidence suggesting that BGN may also act as a signaling 
molecule in addition to acting as a structural component of the ECM 55,60. It is 
firmly established that BGN is part of the innate immune system and plays a 
crucial role in the regulation of inflammation70. New findings indicate that only un-
sequestered BGN is capable of acting as a signaling molecule at least in 
inflammation66,70. Therefore, the amount of BGN in tissue sections does not 
necessarily reflect its biological effect as it represents mainly BGN that has been 
sequestered in the ECM70.  
Reflecting its widespread expression and complex function, it has been 
reported that BGN is involved in numerous experimental and human diseases70, 
including cancer50,55,58. Numerous studies have exhibited that BGN has both 
promoting and inhibitory effects on tumor cells in various cancers66-70. BGN 
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expression has been found to be an indicator of poor prognosis in both colorectal 
and gastric cancer67,69. Conversely, the over-expression of BGN was reported to 
inhibit the growth of pancreatic cancer cells in vitro68. Additionally, HER-2/neu 
mediated oncogenic transformation, the malignant phenotype of these cells, was 
associated with the down-regulation of BGN50.  
 
4.2.3 BGN Over-Expression Decreases Cell Proliferation 
Due to the contradictory roles BGN has been reported to have, the tumor 
progression role that BGN has likely depends on the stage, differentiation, and 
type of tumor. Therefore, to gain a better understanding of BGN in preneoplastic 
breast lesions, I assessed the role of BGN in quiescent, preneoplastic breast 
cells with aberrant AKT activity. Using MCF10A cells genetically altered to 
inducibly express aberrant AKT activity with an iCSZ reporter, we added another 
inducible vector to known-down BGN. With these AKT-expressing, BGN-knock-
down cells, along with just AKT-expressing empty vector cells as a control, I 
plated them using the three-dimensional model system until Day 20. I then 
immune-stained these slides for Ki67 and BGN. As expected, BGN protein 
staining was higher in the control AKT-expressing cells and lower in the AKT-
expressing cells with the BGN-knock-down vector. Since BGN is seen to be over-
expressed in quiescent preneoplastic cells with aberrant AKT activity, I 
hypothesized that BGN plays a role in quiescent maintenance. Therefore, I 
41 
 
expected that knocking-down BGN would increase proliferation in these cells. 
This was the case, the BGN-knock-down cells had a significantly higher percent 
of proliferating cells (Ki67+) than the control cells (Figure 11), but this knock-
down did not cause these cells to transform and grow colonies in soft agar 
(Figure 12). These results suggest that BGN is a cell-intrinsic signal to maintain 
quiescence in normal conditions and led me to hypothesize that over-expressing 
BGN in breast tumor cells may lessen growth. To explore this, I engineered T47D 
cells to constitutively over-express BGN and plated them in a soft agar assay 
comparing them to control T47D cells with an empty vector. This BGN over-
expression vector did increase the expression of BGN (Figure 13). After 3 weeks, 
a noticeable difference in colony-formation was seen between the T47D BGN-
over-expressing cells and the T47D control cells. The T47D control cells had 
more and bigger colonies than the T47D cells with BGN over-expression (Figure 




 Taking advantage of the three-dimensional model system, I investigated 
quiescence maintenance in preneoplastic breast cells with aberrant AKT 
signaling. Overall, quiescent preneoplastic cells with aberrant AKT activation 
displayed a different genetic expression patterns than both quiescent normal 
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cells and proliferating neoplastic cells with aberrant AKT activation. These results 
highlight different functional phenotypes that quiescent preneoplastic cells 
displayed. I discovered that cell-intrinsic signaling played a role in quiescence 
maintenance. Furthermore, the genetic expression patterns of cell-cycle 
machinery were altered as well. An increase in p57Kip2 protein and mRNA 
expression, cyclin-dependent kinase inhibitor, was seen in cells with aberrant 
AKT signaling. Knocking-down p57Kip2 in these cells was sufficient to drive cell 
cycle re-entry suggesting that the cell-intrinsic up-regulation of p57Kip2 was to 
maintain a quiescent state. 
 Additionally, levels of BGN mRNA were significantly higher in quiescent, 
preneoplastic cells with aberrant AKT activation than both normal quiescent cells 
and proliferating preneoplastic cells with aberrant AKT activation. This suggests 
that BGN up-regulation also seems to play a role in quiescent maintenance, but 
since BGN is a secreted protein, BGN regulation of quiescent maintenance 
differs from p57Kip2. As BGN is secreted into the microenvironment, it deposits 
and creates a niche that promotes and favors quiescence. Therefore, the up-
regulation of BGN regulates quiescence maintenance through modulating the 
microenvironment surrounding the cells. This suggests that if the 
microenvironment changes, the favor towards quiescence may be overthrown 
causes cells to clonally expand.  
 Furthering our understanding of similar mechanisms underlying 
quiescence could have broad implications in possibly preventing breast tumor 
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progression from the earliest points of mutation. Furthermore, p57Kip2 and BGN 
may be potential markers in preneoplastic lesions and could be developed further 





















Figure 6: MCF10A myrAKT1 cells up-regulate p57Kip2 protein expression. 
Representative images of AKT induced and control quiescent organoids 











Figure 7: MCF10A myrAKT1 cells up-regulate p57Kip2 mRNA expression. 
qPCR of p57Kip2 mRNA transcript expression normalized to RPLR0. The graph 







Figure 8: p57Kip2 knock-down promotes cell cycle re-entry of MCF10A myrAKT1 
cells. 
a) Representative images and b) quantification of AKT-induced, preneoplastic 
cells with knowndown by two p57Kip2 shRNA and control. Graphs indicate 
means and SEM of 100 organoids from three individual experiments. Statistical 








Figure 9: MCF10A myrAKT1 Quiescent vs. Proliferating mRNA Heatmap 
Comparing myrAKT1 quiescent mRNA (Day 20) and myrAKT1 proliferating (Day 
6) mRNA from MCF10A cells in 3D culture. This list only includes genes that are 




































Figure 10: MCF10A myrAKT1 over-expresses BGN RNA 
Graph shows mRNA levels of BGN in proliferating and quiescent MCF10A GFP 






Figure 11: BGN knock-down increases proliferation in MCF10A myrAKT1 cells 
 a) Representative images and b) quantification of AKT-induced, quiescent BGN-
knock-down and control organoids stained for Ki67 at Day 20. BGN-knock-down 










































Figure 12: BGN knock-down does not promote cell transformation  
Representative images (10x objective) of MCF10A cells with inducible myrAKT1-











Figure 13: BGN over-expression inhibits growth of breast tumor cells 
a) Western blot verification of BGN over-expression. b) Representative pictures 
of soft agar assay of T47D cells over-expressing BGN. 
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Chapter 5: Microenvironment Interactions Promotes 
Clonal Expansion Advantage 
5.1 Introduction 
A hallmark of dormancy is that has the capacity to reverse growth-arrest 
and enter back into the cell cycle34. This ability to exit from a quiescent state is 
the clinically most relevant phase34,56. The expansion of preneoplastic cells 
during premalignant development is fundamental to driving clonal evolution and 
tumorigenesis1. Preneoplastic cells can perplexingly stay latent and resemble 
normal quiescent cells, despite carrying oncogenic drivers. Controls underlying 
this preneoplastic clonal expansion remain largely elusive. Whether a 
preneoplastic quiescent cell re-enters the cell cycle and evolves into a 
proliferating cancer cell depends on environmental cues- this progression is not 
necessarily only intrinsic. Tumorigenic niches have important impacts on this 
progression. Therefore, better understanding preneoplastic, quiescent cells are 
required for elucidation of biochemical and genetic events involving clonal 
evolution during tumor development. 
During the breast tumorigenesis process, preneoplastic cells and the 
stromal environment work hand-in-hand to actively drive tumor progression. 
Quiescent preneoplastic cells are dependent on their surrounding environment 
for cues on whether to remain latent or grow, therefore the stromal 
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microenvironment plays a critical role in tumor initiation and proliferation. 
Mammary epithelial cell growth is dependent on epidermal growth factors 
(EGF)31. EGF is a growth factor that stimulates cell growth, proliferation, and 
differentiation by binding to its receptor, EGFR31. Deregulation of EGF activation 
has been shown to support breast tumor development31 and therefore I wanted 
to see whether this pathway was altered in the preneoplastic quiescent cells 
using the previously mentioned three-dimensional model system. Cells with 
aberrant AKT activation were grown until growth arrest and then exposed to 
different levels of EGF. Even with high levels of EGF-exposure, these cells 
remained in a quiescent state suggesting a homeostatic shift in response to 
growth stimuli. Therefore, these preneoplastic quiescent cells might be sensitive 
to growth stimuli present in the surrounding microenvironment. 
The mechanisms that drive preneoplastic quiescent cells to re-enter the 
cell cycle remain unclear. This critical decision is tightly coupled with interactions 
between preneoplastic cells, host cells, and immune mechanisms. Specific 
immune effectors and secreted factors (including cytokines and chemokines) 
have been implicated in the initiation of tumorigenesis and tumor growth. 
Similarly, inflammation can be associated with increased tumorigenesis as 
chronic inflammation has been associated with a poorer breast cancer prognosis. 
Consequently, the presence or absence of immune effectors is associated with a 
favorable or non-favorable prognosis depending on tissue type, thereby highlight 
the complexity of the host immune system and evolving tumor interaction. This 
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suggests that immune cells are important to the pathogenesis of tumorigenesis2-
4. Understanding the signaling mechanisms that underlie the induction and 
maintenance of preneoplastic quiescence will provide insights into therapeutic 
strategies to delay or intervene with the development of tumors.  
Using a three-dimensional co-culture model system, previous studies have 
investigated the effects of both normal fibroblasts and Carcinoma-associated 
fibroblasts (CAFs) on preneoplastic breast cells. Results showed that normal 
mammary fibroblasts seemed to inhibit proliferation, while CAFs induced 
epithelial cell growth and morphogenesis. Therefore, balancing between tumor-
promoting and tumor-suppressive effects of CAFs may hinge on the 
heterogeneity of CAF populations, as well as other components in the 
microenvironment.  Altogether, breast CAFs support breast cancer proliferation 
via secretion of various growth factors and cytokines, but the mechanisms 
underlying the upregulation of these factors, downstream pathways, and the 
cross-talk between factors is not clear. Even further, it is unclear whether these 
secreted factors from breast CAF are the consequence of cancer or if initiated 
before cancer transformation.  Despite the understanding of characteristics 
associated with breast CAFs, further investigation into their role and involvement 
of the breast cancer microenvironment will yield important and needed insights to 
the convoluted connections between cancer cells and the stroma. 
Given the increasing importance of immune-oncology and the dramatic 
rise in the use of targeted therapy in the clinic, I investigated the role of the 
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immune system in clonal expansion in preneoplastic breast cells. Here, using 
organoid models of quiescent preneoplastic breast cells with aberrant AKT 
activation, I found that distinct molecular controls in the preneoplastic cells 
contribute to an altered homeostatic state of quiescence, which underlies the 
maintenance of growth-arrest under normal conditions and the proliferative 
advantage in suppressive tissue environments. These quiescent preneoplastic 
cells express increased levels of the cycling-dependent kinase inhibitor p57Kip2 
to sustain growth-arrest, despite AKT hyperactivation, as previously mentioned. 
Concurrently these cells show an upregulation of CXCR4 expression that confers 
the cells competence to proliferate in response to CXCL12, a chemokine 
implicated in cancer-associated stroma. CXCL12 promotes proliferation through 
ERK and PKA, does not induce neoplastic transformation, but suffices to drive 
clonal expansion in suppressive mammary organoids. Our studies propose a 
model in which an oncogene-mediated switch of mitogen usage promotes 





5.2.1 EGF is not Sufficient to Promote Outgrowth 
Mammary epithelial cell growth is dependent on epidermal growth factors 
(EGF)31. EGF is a growth factor that stimulates cell growth, proliferation, and 
differentiation by binding to its receptor, EGFR31. Deregulated EGF activation has 
been shown to support breast tumor development31. I first tested whether 
quiescent preneoplastic cells are prone to proliferate in elevated levels of 
exogenous EGF. I exposed the growth-arrested organoid cells with aberrant AKT 
activation or controls to media with increasing EGF levels up to four times 
(20ng/mL) the original condition (Figure 14), a concentration significantly higher 
than the reported serum EGF concentration (~0.6ng/ml) 32. Surprisingly, both the 
control and the AKT-induced, preneoplastic cells remained largely quiescent, 
suggesting that these quiescent preneoplastic cells are no longer sensitive to 
EGF-induced proliferation.  
 
5.2.2 CAFs Promote Cell-Cycle Re-Entry  
I hypothesized that quiescent preneoplastic cells are more prone to 
proliferate in stromal environments associated with increased cancer risk 
secreted factors. Premalignant cells in tissue fields surrounding resected tumors 
have been implicated in the development of second or recurrent tumors35,36. 
CAFs are key components of breast tumor-associated stroma that often persist 
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with residual preneopalstic cells after tumor resection and have been shown to 
secrete factors that contribute to tumor development37. I therefore took 
advantage of an established CAF model, cavioln-1 knockout (Cav1-KO) NIH3T3 
cells, with a secretome similar to human breast CAFs38,39, to test my hypothesis 
and explore the proliferative control of quiescent preneoplastic cells. I exposed 
AKT-induced, quiescent preneoplastic cells to conditioned-media (CM) from 
CAFs or control fibroblasts, and determined their proliferative responses (Figure 
15 A). I found that exposure to CM from Cav1-KO fibroblasts significantly 
increased the percent of proliferating cells (Ki67+) in the quiescent preneoplastic 
organoids (Figure 15 B, C), suggesting that stromal environments with CAFs may 
favor clonal expansion of quiescent preneoplastic cells.  
 
5.2.3 CXCL12 Signaling Drives CAF-Promoted Cell-Cycle Re-Entry 
To gain mechanistic insights into this CAF-induced proliferation, I 
identified secreted factors upregulated in the Cav1-KO fibroblasts using 
quantitative mass spectroscopy. I focused on CAF-derived chemokines because 
they have been implicated in mediating stromal-epithelial crosstalk36,39. I found 
that three chemokines, CXCL1, CXCL7, and CXCL12, are significantly more 
abundant in the Cav1-KO CM than the control (Figure 16 A). To determine their 
role in the observed phenotypes, I examined the proliferative response of these 
quiescent preneoplastic cells when systematically exposed to the mentioned 
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chemokines individually. I found that recombinant CXCL12, but not CXCL1 nor 
CXCL7, drives a subtle but significant increase in the percent of proliferating cells 
per organoid (Figure 16 B, C). Importantly, previous studies have shown that 
CXCL12 is upregulated in carcinoma-associated fibroblasts from breast and 
pancreatic cancer patients36,40. The mechanisms underlying the small percentage 
of cells that exit quiescence and proliferate in response to CXCL12 is unclear, 
but may reflect additional homeostatic controls that restrain proliferation of 
preneoplastic cells and suppress tumorigenesis during early development.  
Previous studies have demonstrated that CXCL12 plays a critical role in 
promoting malignant cell growth, angiogenesis, and metastasis in advanced 
stages of tumorigenesis36,43,44, but its contribution to premalignant development 
is unclear. I further investigated the CXCL12-mediated signaling crosstalk to the 
quiescent preneoplastic cells. I found that CXCL12 selectively drives proliferation 
of the AKT-induced, quiescent preneoplastic cells, but not the control quiescent 
cells (Figure 17). This CXCL12-induced selective proliferation was also observed 
in MCF12A cells overexpressing myrAKT1 and MCF10A cells overexpressing 
AKT1-E17K (Figure 18). Notably, in addition to CAFs, upregulation of CXCL12 is 
also evident in other cellular conditions associated with increased cancer risk, 
such as aging (senesced fibroblasts) 41 and obesity-induced inflammatory tissue 
environments42. Together, these data demonstrated a role of stromal conditions 
in promoting selective proliferative outgrowth of preneoplastic cells and identified 
CXCL12 as a key factor mediating this selective proliferative response.  
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5.2.4 CXCL12 Promotes Cell-Cycle Re-Entry Through PKA and MEK via CXCR4 
To elucidate the molecular basis underlying this selective proliferation 
response, I examined the expression of two CXCL12 receptors, CXCR4 and 
CXCR745, in the quiescent preneoplastic cells. I found that mRNA transcription of 
CXCR4 is increased in the AKT-induced, quiescent preneoplastic cells compared 
to the control quiescent cells, which CXCR7 mRNA transcripts were undetectable 
by qPCR (Figure 19 A, B). Immunofluorescent staining also showed an increase 
in the abundance of CXCR4 proteins on the cell membrane of quiescent 
preneoplastic cells with aberrant AKT activation (Figure 19 C). Functionally, I 
found that inhibiting CXCR4 with AMD3100, specific CXCR4 antagonist, 
significantly blocked the CXCL12-induced proliferation (Figure 20). Similar effects 
were found in MCF10A cells with inducible AKT1-E17K and MCF12A cells with 
activated myrAKT1 (Figure 21). AMD3100 also blocked proliferation induced by 
the CM from Cav1-KO fibroblasts (Figure 22). Moreover, I examined the 
signaling downstream of CXCR4 in mediating the CXCL12-induced proliferation. 
Treatment with inhibitors of MEK (PD325901) and PKA (H-89), but not PKC 
(GF109203X) (Figure 23), blocked the proliferative outgrowth. These data 
together suggest that CXCL12 induced proliferation of preneoplastic cells 
through CXCR4, MEK, and PKA signaling. Furthermore, I determined whether 
this CXCR4-mediated proliferation requires continual aberrant activation of AKT 
signaling. Cell lines were generated with an inducible CXCR4 expression 
cassette and I found that overexpressing CXCR4 alone, without overexpressing 
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myrAKT1, in quiescent organoid cells is sufficient to confer proliferative response 
to exogenous CXCL12 (Figure 24). Altogether, these data suggest that the AKT-
induced upregulation of CXCR4 during growth-arrest underlies the selective 
competence of the quiescent preneoplastic cells to proliferate in response to 
exogenous CXCL12 derived from CAFs or other tumor-promoting 
microenvironments.  
Successful clonal expansion depends on not only cell proliferation but also 
survival of the progeny. To gain biological insights into the CXCL12-induced 
proliferation, I determine its contribution to successful clonal expansion of 
preneoplastic cells in the premalignant organoids. I transduced single-cells with 
low doses of myrAKT1-IRES-GFP, or IRES-GFP control, lentivectors in growth-
arrested mammary organoids and determined the clonal expansion of 
transduced cells after exposing the organoids to CXCL12. Single cells 
transduced with myrAKT1 or GFP control remain largely as single-cells under 
normal growth conditions, consistent with the maintenance of quiescence in 
preneoplastic cells (Figure 25 A). CXCL12 treatment significantly promoted 
clonal expansion of transduced preneopalstic cells with aberrant AKT activation, 
but not in the GFP control (Figure 25 B). Interestingly, CXCL12 treatment did not 
drive anchorage-independent growth of either AKT-induced preneoplastic cells 
and control cells on soft agar (Figure 26). These data support that CXCL12 
promotes selective preneoplastic clonal expansion in premalignant tissue prior to 




5.2.5 Increased CXCR4 Expression Favors Breast Tumor Initiation and 
Progression 
Lastly, my findings of CXCR4 signaling in promoting preneoplastic clonal 
expansion predicts that elevated CXCR4 expression level favors breast tumor 
initiation and progression. Consistent with this notion, quarry of patient sample 
databases (OncomineTM) show a significant increase in CXCR4 transcription in 
early stage breast ductal carcinoma in situ (3.0 folds, p=8.43E-7) and invasive 






A hallmark of dormancy is the capacity to reverse growth-arrest and enter 
back into the cell cycle. This ability to exit from a quiescent state is the clinically 
most relevant phase as the expansion of preneoplastic cells during premalignant 
development is fundamental to driving clonal evolution and tumorigenesis. 
Although I gained more understanding into the cell-intrinsic mechanisms that 
help maintain quiescence by altering the genetic expression within the cells and 
how these mechanisms can modulate the environment to promote quiescence, it 
is unclear what triggers preneoplastic cells with pro-growth, oncogenic alterations 
to surpass this maintenance and re-enter the cell cycle. Whether a preneoplastic 
quiescent cell re-enters the cell cycle and evolves into a proliferating cancer cell 
may not necessarily be only intrinsic, but can depend on environmental cues. 
Tumorigenic niches have important impacts on this progression. Therefore, a 
better understanding preneoplastic, quiescent cells are required for elucidation of 
biochemical and genetic events involving clonal evolution during tumor 
development.  
Using the previously mentioned reconstructed quiescent preneoplastic 
model with aberrant AKT activation, I elucidated the control of indolent 
preneoplastic cells during premalignant development. Exposing these aberrant 
AKT quiescent cells to high levels of EGF, there was no growth suggesting that 
these cells are insensitive to their native growth factor and assume an altered 
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homoestatic state that upregulates p57Kip2 and BGN secretion to sustain 
growth-arrest in normal conditions, while concurrently inducing the expression of 
CXCR4. Although EGF is present in the organoid cultures, the AKT-induced 
quiescent preneoplastic cells appear to be insensitive to EGF-stimulated 
proliferation, prompting me to investigate the growth regulation in these 
preneopalstic cells. Since cytokines and chemokines are known to be present 
surrounding preneoplastic lesions and breast tumors secreted from fibroblasts 
and CAFs, looking at the secretome for possible growth factors that promote 
proliferation of the quiescent, preneoplastic cells in replacement of EGF. Results 
showed a high secretion of CXCL12 that cells with aberrant AKT activation were 
selectively sensitive to compared to control cells. Additionally, an up-regulation of 
receptor CXCR4 protein and mRNA, who’s major ligand is CXCL12, was seen in 
preneoplastic quiescent cells as well. This CXCR4 up-regulation confers the 
quiescent cells to selective capacity to respond to CXCL12. CXCL12 acts as an 
alternate mitogen derived from tumor-associated stroma, which promotes 
quiescent preneoplastic cells to proliferate and drives selective clonal expansion 
in a suppressive epithelial environment, ultimately replacing the native role of 
EGF. Furthermore, with the use of inhibitor studies, results show that the 
CXCL12-CXCR4 axis was signaling through PKA, MEK, and ERK in the 
preneoplastic, quiescent cells.  
Altered homeostatic control of quiescence has emerged as a mechanism 
in muscle stem cells and resting T-cells that underlie normal physiological 
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functions critical for muscle repair and immune response47,48. My findings 
suggest that altered homeostatic controls of quiescence may also underlie the 
maintenance and selective clonal expansion of indolent preneoplastic cells 
during premalignant development. I demonstrated, in my model, an altered 
homeostatic control of quiescence mediated by aberrant AKT signaling and a 
mechanism of selective clonal expansion driven by a CAF-derived chemokine in 
a premalignant tissue environment. These specific findings seem to be selective 
for quiescent cells with an altered AKT pathway rather than universal for all 
preneoplastic quiescent cells with different oncogenic alterations. The specific 
homeostatic mechanisms will likely depend on the underlying oncogenic changes 










Figure 14: Cells remain growth-arrest despite different EGF concentrations. 
a) Representative images and b) quantification of GFP and myrAKT/GFP over-
expressing organoids at Day 20 culture two days after doxycycline induction at 








Figure 6: CAF conditioned media promotes outgrowth of MCF10A myrAKT1 cells 
a) Schematic of organoid treatment with conditioned media from carcinoma-
associated fibroblast models. b) Representative images and c) quantification of 






Figure 7: CAF-secreted CXCL12 mediates outgrowth of MCF10A myrAKT1 cells 
a) Up-regulation of chemokines in CAV1-KO fibroblasts. Proteins in serum-free 
conditioned meda from Cav1-KO and control fibroblasts were analyzed via 
LC/MS/MS. Three chemokines CXCL1, CXCL7, and CXCL12 were up-regulated 
more than two folds in the CAV1-KO conditioned media. b) Representative 
images and c) quantifications of AKT-induced premalignant organoids treated 
with 50ng/ml of CXCL1, CXCL7, CXCL12, or vehicle. Scale bar, 10μm. Graphs 
indicate means and SEM of 100 organoids from three individual experiments. 
Round dots represent individual data points. Statistically significant differences 







Figure 8: Recombinant CXCL12 promotes proliferation of MCF10A myrAKT1 
cells 
 a) Representative images and b) quantification of AKT-induced, quiescent 
premalignant and control organoids treated with recombinant human CXCL12 or 
vehicle control. CXCL12 selectively promotes proliferation of the preneoplastic 





Figure 9: Recombinant CXCL12 selectively promotes outgrowth in AKT mutated 
cells 
 Quiescent organoids derived from a) MCF10A/AKT-E17K or MCF10A/GFP 
control and b) MCF12A/myrAKT1 or MCF12A/GFP control were treated with 
recombinant CXCL12 or vehicle. Representative images and quantification of 
proliferative cells after treatment are shown. CXCL12 promotes proliferative 
outgrowth in both quiescent preneoplastic cell models with aberrant AKT 
activation. Graphs indicate means and SEM of 100 organoids from three 
individual experiments. Round dots represent individual data points. Statistically 








Figure 10: MCF10A myrAKT1 cells up-regulate CXCR4 protein and mRNA. 
 a) qPCR (mRNA level normalized to RPLPO), b) Western blots (protein), and c) 
immunostaining of CXCR4 in quiescent preneoplastic cells with aberrant AKT 





Figure 11: AMD3100 prevents CXCL12-mediated outgrowth. 
a) Representative images and b) quantification of AKT-induced, quiescent 
preneoplastic cells treated with CXCL12 or CAV-1 KO CM in the presence of the 










Figure 12: CXCR4 over-expression in control cells promotes outgrowth 
Representative images and quantification of cell proliferation from growth-
arrested MCF12A organoids induced to overexpress CXCR4-IRES-GFP or 
IRES-GFP control in media containing recombinant human CXCL12. CXCR4 
overexpression is sufficient to confer sensitivity to exogenous CXCL12. The 
graph indicates means and SEMs of 100 organoids from three individual 
experiments. Round dots represent individual data points. Statistically significant 




Figure 13: AMD3100 blocks CAF-mediated outgrowth of MCF10A myrAKT1 
cells. 
a) Representative images and b) quantification of AKT-induced, quiescent 
preneoplastic cells treated with CXCL12 or CAV-1 KO CM in the presence of the 
specific CXCR4 antagonist AMD3100 or vehicle (PBS). The graph indicates 
means and SEMs of 100 organoids from three individual experiments. Round 
dots represent individual data points. Statistically significant differences were 











Figure 14: AMD3100 blocks CXCL12-mediated outgrowth in AKT-mutated cells. 
Representative images and quantification of cell proliferation in two additional 
organoid models of quiescent preneoplastic cells with aberrant AKT activation. 
Growth-arrested organoids derived from MCF10A cells with inducible AKT1-
E17K-IRES-GFP or IRES-GFP control and MCF12A cells with inducible 
myrAKT1-IRES-GFP or IRES-GFP control were treated with CXCL12 in the 
presence of the CXCR4 inhibitor AMD3100 or vehicle control. The CXCR4 
antagonist significantly blocked CXCL12-induced proliferation in both cell 
models. The graph indicates means and SEMs of 100 organoids from three 
individual experiments. Round dots represent individual data points. Statistically 







Figure 15: CXCL12 promotes outgrowth through PKA and MEK. 
Quantification of AKT-induced preneoplastic cells treated with CXCL12 in the 
presence of H-89 (PKA inhibitor), GP1092033X (PKC inhibitor), PD325901 (MEK 







Figure 16: CXCL12 promotes outgrowth of single-infected myrAKT1 cells 
a) Clonal expansion analysis of transduced single cells in growth-arrested 
mammary organoids. Nuclei are outlined with dotted white line to aid 
visualization. b) Percent of expanded clones (GFP-positive clusters with more 
than one nucleus) were determined from 80-120 organoids per sample. Means 
and standard deviation from three individual experiments were graphed. Round 
dots represent individual data points. Statistically significant differences were 









Figure 17: CXCL12-mediated outgrowth does not transform MCF10A cells. 
Representative images (10x objective) of MCF10A cells with inducible myrAKT1-
iGSP or IRES-GFP cultured in soft-agar with media containing 1μg/ml Dox and 
50ng/ml CXCL12 or vehicle for 30 days. Cells were plated at 10,000 cells per 
well of 6-well tissue culture plate. Media were refreshed every 3 days. No colony 







Figure 18: Increased CXCR4 expression correlates with premalignant breast 
lesions. 
Query of CXCR4 mRNA transcript expression in breast samples from Oncomine 
(ThermoFisher Scientific).  Increased CXCR4 expression correlates with 





















Figure 19: Model of selective clonal expansion of myrAKT1 cells  
Model of selective clonal expansion of preneoplastic cells with aberrant AKT 
activation in permissive stromal environments.  Blue, basement membrane. 
Gray, normal quiescent cells. Pink, primed quiescent state with AKT-induced 
upregulation of p57Kip2 and CXCR4. Pink with red outline, proliferative 
preneoplastic cells with aberrant AKT signaling. 
AKT 
































Chapter 6: Conclusion 
6.1 Introduction 
With breast cancer being one of the most commonly diagnosed cancers 
among women, cancer prevention would have a profound impact on cancer-
associated mortality and morbidity. To potentially achieve this, in-depth 
knowledge of physiological processes underlying the multi-step and linear 
progression of tumor initiation is required. In principle, tumor prevention would 
imply the protection against tumor initiation or an efficacious preventative 
strategy to block the evolution of initiated cells to malignancy. Since there is no 
way to determine the presence of preneoplastic lesions by reviewing 
mammograms or other breast imaging tools, understanding how preneoplastic 
quiescent cells in preneoplastic lesions are able to maintain quiescence while 
carrying oncogenic changes and understanding what permissive environments 
allows them to be advantageous in clonal expansion is needed. Creating a more 
comprehensive picture of the controls and regulations that allow and prevent 
evolution and clonal expansion of preneoplastic cells into neoplastic lesions and 
potentially tumors may provide novel markers. These markers could improve 
detection, diagnosis, and help strengthen current preventative strategies, 




6.2 Modeling Preneoplastic Quiescence 
With cancer models being the primary tool used by cancer researchers in 
order to test specific hypotheses related to cancer and ultimately gain an overall 
better understanding of the mechanisms underlying cancer, gaining mechanistic 
insight into preneoplastic, quiescent cells have been difficult due to a lack of 
model systems that allow a simplistic systemic manipulation that also 
recapitulates both the cellular and molecular context of native tissue. Combining 
genetically altered MCF10A to over-express pro-growth signals with a three-
dimensional cell culture system allowed for these cells to model preneoplastic 
cells in a quiescent state. Furthermore, this model is able to mimic the molecular 
context unlike traditional cell culture, but also provides a context in which it is 
feasible to identify genes and dissect mechanisms necessary to produce 
phenotypic alterations similar to those observed during malignant progression, 
while also allows for the application of non-genetic factors to investigate cellular 
mechanisms that govern preneoplastic quiescence, which is not as simple to 
extrapolate in animal models.  
This organotypic system provides a model to study the maintenance of 
preneoplastic, quiescent cells that contain defined oncogenic alterations. Using 
cells with aberrant AKT expression as a model for the early genetic changes in 
preneoplastic cells is representative of all preneoplastic lesions with pro-growth, 
oncogenic alterations and it allows for insight into the underlying mechanisms of 
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preneoplastic lesions in general. It also permits convenient genetic manipulation 
and application of non-genetic factors to investigate cellular mechanisms that 
govern preneoplastic quiescence. Furthermore, when these quiescent, 
preneoplastic cells re-enter the cell cycle, the low proliferation rates seen in this 
model mimic the low proliferation rates seen in preneoplastic lesions. Altogether, 
these organoid models recapitulate the genetic and proliferative features of 
quiescent breast preneoplastic cells and, importantly, provide a platform to 
interrogate the cellular control of quiescent preneoplastic cells at the mechanistic 
level.  
This model system overcomes the major barrier that has impeded 
investigation of preneoplastic clonal expansion and understanding the underlying 
mechanisms that regulate and maintain quiescence. Due to its more 
physiologically relevant environment, a more comprehensive understanding of 
the regulatory mechanisms and conditions that govern the state of preneoplastic 
quiescence can be obtained leading to the identification of useful markers of 
these cells and health conditions. Furthermore, this model system can be used in 
other contexts beyond what is presented in this thesis research. Other cells lines 
with other oncogenic changes may be explored more in-depth to form a better 
understanding of the specific alterations preneoplastic quiescent cells undergo to 
maintain quiescence and be advantageous in permissive environments. Using 
this model system to explore other cell lines and oncogenic changes, will help 
identify more universal preneoplastic markers, as well as, oncogene-specific 
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markers. Identifying potential markers and developing prognostic markers could 
be used to evaluate patients’ cancer risks potentially leading to a reduction in 
cancer mortality and develop stronger tumor prevention strategies. 
  
 
6.3 Maintenance of Quiescence 
A critical stage in early breast tumorigenesis is the emergence of 
preneoplastic cells that carry key tumor drivers but remain in a latent state similar 
to normal quiescent cells. Such latent preneoplastic cells have been reported in 
precancerous lesions and tissues surrounding tumors, and are implicated as 
precursors for primary tumors. Evidence has shown that quiescence is a distinct 
state, and does not reflect a longer G1 phase. Cells enter quiescence in 
response to an absence of growth factors or situational cues. It is perplexing that 
preneoplastic cells can remain in a quiescent state, similar to normal quiescent 
cells, despite carrying pro-growth genetic alterations. Therefore, understanding 
and identifying the distinguishing characteristics and signaling mechanisms that 
underlie the induction and maintenance of preneoplastic quiescence from 
proliferating preneoplastic cells will provide insights into therapeutic strategies to 
delay or intervene with the development of tumors.  
Taking advantage of the three-dimensional model system, I investigated 
quiescence maintenance in preneoplastic breast cells with aberrant AKT 
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signaling. AKT promotes a variety of different functions in the cell including cell 
survival and cell proliferation. AKT is also a major tumor driver found in early 
lesions of the breast and may other epithelial tissues. Using aberrant AKT 
signaling as a model for preneoplastic cells with oncogenic alterations, I 
discovered cell-intrinsic signaling that played a role in quiescence maintenance. 
Overall, quiescent preneoplastic cells with aberrant AKT activation 
displayed a different genetic expression patterns than both quiescent normal 
cells and proliferating neoplastic cells with aberrant AKT activation. These results 
highlight different functional phenotypes. Furthermore, the genetic expression 
patterns of cell-cycle machinery were altered as well. An increase in p57Kip2 
protein and mRNA expression, cyclin-dependent kinase inhibitor, was seen in 
cells with aberrant AKT signaling. Knocking-down p57Kip2 in these cells was 
sufficient to drive cell cycle re-entry suggesting that the cell-intrinsic up-regulation 
of p57Kip2 was to maintain a quiescent state.  
Similarly, levels of BGN RNA were significantly higher in quiescent, 
preneoplastic cells with aberrant AKT activation than both normal quiescent cells 
and proliferating preneoplastic cells with aberrant AKT activation. This suggests 
that BGN up-regulation also seems to play a role in quiescent maintenance. 
Using MCF10A cells with aberrant AKT signaling, I knocked down BGN and saw 
that quiescence maintenance was disturbed and the cells re-entered the cell 
cycle. Furthermore, increasing BGN expression in breast tumor cells (T47D) 
significantly decreased proliferation and colony formation in soft agar assays. 
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These results suggest that the up-regulation of BGN is another cell-intrinsic 
signaling mechanism in order to maintain quiescence in preneoplastic cells with 
aberrant AKT signaling. Although a cell-intrinsic signaling mechanism, it differs 
from p57Kip2 over-expression due to the fact that BGN is a secreted molecule. 
Therefore, up-regulation of BGN is being secreted into the microenvironment and 
modulating the microenvironment to create a niche that prevents clonal 
expansion.  
 
6.4 Clonal Expansion Advantage 
A hallmark of dormancy is the capacity to reverse growth-arrest and enter 
back into the cell cycle. This ability to exit from a quiescent state is the clinically 
most relevant phase as the expansion of preneoplastic cells during premalignant 
development is fundamental to driving clonal evolution and tumorigenesis. 
Although I gained more understanding into the cell-intrinsic mechanisms that 
help maintain quiescence, it is unclear what triggers preneoplastic cells with pro-
growth, oncogenic alterations to surpass this maintenance and re-enter the cell 
cycle. Whether a preneoplastic quiescent cell re-enters the cell cycle and evolves 
into a proliferating cancer cell may not necessarily be only intrinsic, but can 
depend on environmental cues. Tumorigenic niches have important impacts on 
this progression. Therefore, a better understanding preneoplastic, quiescent cells 
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are required for elucidation of biochemical and genetic events involving clonal 
evolution during tumor development.  
Preneoplastic cells and the stromal environment work hand-in-hand to 
actively drive tumor progression, so I investigated the effects of both normal and 
cancer-associated fibroblasts on preneoplasic, quiescent cells with aberrant AKT 
signaling. Previous studies have showed that normal fibroblasts seemed to inhibit 
proliferation, while CAFs induced cell growth. Results showed an oncogene-
mediated switch of mitogen usage promotes selective preneoplastic clonal 
expansion in permissible microenvironments.  
Since EGF is the native growth factor for breast epithelial cells and I had 
previously shown that there is a change in cell-cycle machinery in quiescent cells 
with aberrant AKT signaling, I exposed high levels of EGF to these quiescent 
preneoplastic cells using the three-dimensional model system to see whether 
higher levels of native growth factor could provoke cell-cycle re-entry. Even with 
high levels of EGF-exposure, these cells remained in a quiescent state 
suggesting a homeostatic shift in response to growth stimuli. phenotypes and the 
altered homeostatic state and response to growth stimuli that quiescent 
preneoplastic cells displayed. These results are similar to previously reported 
results suggesting that deregulated EGF signaling is likely to play a role in breast 
tumor progression. Due to the EGF insensitivity of quiescent cells with aberrant 
AKT signaling, it is suggested that there is an altered homeostatic state and 
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response to growth stimuli which may be switched to be sensitive to other growth 
stimuli.  
The critical decision to re-enter the cell cycle is tightly coupled with 
interactions between preneoplastic cells, host cells, and immune mechanisms. 
Specific immune effectors and secreted factor (including cytokines and 
chemokines) have been implicated in the initiation of tumorigenesis and tumor 
growth. Therefore, using the three-dimensional model system and preneoplastic, 
quiescent cells with aberrant AKT signaling, I exposed normal and CAF 
conditioned-media to see whether quiescence maintenance was disturbed since 
CAFs have been known to be present in preneoplastic and neoplastic 
microenvironments and play a role in tumor progression. As a result, 
preneoplastic quiescent cells exited quiescence and showed a significantly 
higher amount of proliferation. To elucidate what secreted factor was 
responsible, CAF conditioned-media was looked into further and chemokine 
CXCL12 showed to mediate cell cycle re-entry of quiescent cells with aberrant 
AKT signaling. Furthermore, CXCL12-mediated proliferation signaled through the 
CXCR4 receptor, PKA, and MEK. To determine whether quiescent preneoplastic 
cells with aberrant AKT signaling were primed for this signaling, I compared 
CXCR4 expression in preneoplastic quiescent cells with aberrant AKT signaling 
and normal quiescent cells. Results showed a higher mRNA and protein 
expression of CXCR4 in quiescent cells with aberrant AKT, suggesting that these 
preneoplastic cells were primed to have an advantage to clonally expand in this 
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specific permissive environment. Therefore, although quiescent cells with 
aberrant AKT activation had cell-intrinsic signals to maintain quiescence, they 
also expressed a mechanism to make them advantageous in selective clonal 
expansion driven by CAF-derived chemokine in a premalignant tissue 
environment.  
 
6.5 Overall Implications 
Using the three-dimensional quiescent model together with preneoplastic 
cells expressing aberrant AKT activation, I was able to gain mechanistic insight 
into cell-intrinsic homeostatic alterations for quiescence maintenance and also 
understand mechanisms that gave these cells a clonal expansion advantage in 
certain environments. Overall, my thesis research has brought to light how 
complex the system that surrounds preneoplastic cell quiescence is. My results 
showed that preneoplastic quiescent cells not only alter intrinsically by up- and 
down-regulating the genetic expression of various proteins, but are able to alter 
their surrounding environment to help maintain quiescence, as well as, prime 
themselves to be advantageous in a permissive environment to clonally expand. 
Although the specifics of my research will not be universal to all preneoplastic 
lesions, the three overarching themes of intrinsic quiescence maintenance, 
extrinsic quiescence maintenance, and clonal expansion advantage may be. 
These three themes should be further explored to gain an understanding of the 
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specific mechanisms of other underlying oncogenic changes and tissue origins of 
preneoplastic cells. With this deeper mechanistic insight into quiescent 
preneoplastic breast cells, novel prognostic markers can be identified which will 
help improve prevention strategies. In conjunction with underlying oncogenic 
changes and tissue origins, using novel prognostic markers could help determine 
whether the lesions in question should be considered more high-risk and low-
risk, help improve detection, and make prognosis clearer. From there, the 
appropriate action can be taken to inhibit or slow down progression, overall 
improving and strengthening preventative strategies resulting in a decrease in 
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